Alterity Therapeutics Ltd (PRNAF)

Overview

Alterity Therapeutics Limited is at the forefront of developing therapeutic drugs aimed at combating a range of debilitating neurological disorders, including Alzheimer's disease, Huntington disease, and Parkinson's disease, with its operations rooted in Australia. Originally known as Prana Biotechnology Limited, the company underwent a rebranding to Alterity Therapeutics Limited in April 2019, a change that reflects its evolving focus and ambition within the biotechnology sector. Since its inception in 1997, Alterity Therapeutics has been committed to advancing medical research and clinical trials to bring innovative treatments to patients globally, reflected in their active clinical pipeline and research endeavors. The organization is headquartered in Melbourne, Australia, positioning itself as a key player in the biotech industry, both nationally and internationally.

Products and Services

• ATH434

  Currently in Phase I clinical trial, ATH434 represents Alterity Therapeutics' leading drug candidate, specifically targeting the treatment of Parkinson's disease. This innovative therapeutic approach exemplifies the company's commitment to addressing the complex challenges of neurodegenerative disorders through advanced scientific research and development.

• ATH434-201

  ATH434-201 is another key development within the company’s portfolio, currently in Phase II clinical trial aimed at treating multiple system atrophy at its early stage. This indicates a significant step towards providing treatments for conditions that have limited therapeutic options available, showcasing the company's dedication to expanding its impact on neurodegenerative diseases.

• ATH434-202

  This variant of the ATH434 series is geared towards treating advanced multiple system atrophy, also in Phase II clinical trial. By developing targeted treatments for different stages of the same disease, Alterity Therapeutics is working towards a comprehensive solution that could potentially improve the quality of life for patients across various progression levels of the disorder.

• PBT2

  PBT2 has completed a Phase 2a clinical trial aimed at treating Alzheimer's disease, marking a pivotal milestone in the company's quest to combat one of the most challenging neurodegenerative disorders. While still under development, PBT2’s progress is a testament to Alterity Therapeutics' ongoing efforts to pioneer drug discovery and development in the neurological domain.